Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation
Which stocks are undervalued right now? Check free
Discover now →
Cochlear Limited (CHEOF) fair value: what the stock is really worth
As of Oct 2, 2026: fair value of Cochlear Limited $63.79, price $93.61, upside -31.9%, quality 70 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
- Fair value above price? No
- Good quality? Yes
- Add to watchlist
CL
Broad data
Sep 23, 2026
Broad data
Sep 23, 2026
Cochlear Limited
CHEOF · USOvervalued / MonitorQuality is not strong enough to offset the price risk.
!Fair value $63.79 · Overvalued (−31.9%)
✓Quality 70/100
!Mixed Growth (revenue 5y +12.2 %/yr)
✓Solidly profitable · 14.8% net margin (TTM)
✓Low debt · generates free cash flow
!4.6% dividend yield · Pays more than it earns
✓Wide moat 71/100
Watch Cochlear Limited for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.
Watch for free
Pro now: $1 first month
What runs behind every stock
26
valuation models
8 families, DCF to NCAV
37
quality factors
margins, balance sheet, cashflow, debt
6
AI factors
moat, what no ratio measures
2,000+
data points
verified, per stock, median
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 23, 2026.
How to read this chart
60‑month range $47.45 – $224.37 · fair‑value band $35.64 – $90.53 · the $93.61 price screens above the $63.79 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 23, 2026.
Company profile
Cochlear Limited provides implantable hearing solutions for children and adults worldwide. The company offers cochlear implant systems, sound processor upgrades, bone conduction systems, and other products.
Show more
Cochlear Limited provides implantable hearing solutions for children and adults worldwide. The company offers cochlear implant systems, sound processor upgrades, bone conduction systems, and other products. It also provides cochlear nucleus systems, including Nucleus sound processors, smart bimodal hearing solution, and Nucleus implants; cochlear Baha systems comprising Baha 6 max sound processor and Baha implant; and accessories, such as wireless devices and Nucleus water-safe accessories. The company was founded in 1981 and is headquartered in Sydney, Australia.
Stock analysis
Cochlear Limited (CHEOF) currently trades at $93.61, while our model-based Fair Value estimate is $63.79, 31.9% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of $72.92 per share, and 1 of the 26 models we run sit above the $93.61 price.
Bear case: the Asset-Based group reads lowest at $13.90, and 25 of the 26 models stay below the price. Evidence for this calculation is high.
Scenario range: $35.64 (bear) to $90.53 (bull), the price of $93.61 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 70/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Cochlear Limited reported revenue of A$2.3B in FY2025 versus A$1.5B in FY2021, a compound +11.8%/yr. Reported net income was A$389M in FY2025, compounding +4.5%/yr from FY2021.
Key figures
Market cap $6.1B · P/E ratio 25.1 · P/S ratio 4.17 · EPS (TTM) $3.73 · Dividend yield 4.6% · Net margin 16.6% · Return on equity 18.2% · Return on assets (EBIT) 15.7%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 55 out of 100 (medium confidence).
What moves the price
The share trades about 52% below its 52-week high and 45% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 6% fair-value upside, at −32%, CHEOF screens richer than that median.
Fair Value models
Bear $35.64
Fair Value $63.79
Bull $90.53
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.
Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.
Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
FCF DCF
$20.13
$31.97
$50.82
79
Growth DCF
$20.11
$31.22
$48.43
77
Owner Earnings
$46.26
$75.62
$122.34
75
All 26 models by family
DCF Models
FCF DCF
$20.13
$31.97
$50.82
79
Owner Earnings
$46.26
$75.62
$122.34
75
5Y Revenue Exit
$33.60
$59.30
$93.97
71
5Y EBITDA Exit
$39.48
$70.98
$109.90
74
5Y P/E Exit
$49.15
$90.21
$136.20
69
10Y Revenue Exit
$27.32
$49.61
$83.05
65
10Y EBITDA Exit
$32.30
$57.80
$95.63
66
10Y P/E Exit
$38.48
$71.29
$116.40
62
Earnings-Based
Graham-Dodd
$28.13
$114.08
$155.24
64
Lynch FV
$28.53
$40.75
$52.98
61
PEG = 1.0
$28.53
$40.75
$52.98
57
EPV
$29.20
$33.42
$37.06
74
Dividend Discount
Gordon GGM
$25.99
$51.79
$78.43
67
DDM Multi-Stage
$25.99
$44.76
$54.67
67
Multiples
P/E Multiple
$68.27
$91.02
$113.78
63
P/S Multiple
$52.75
$70.33
$87.92
58
P/B Multiple
$52.75
$70.33
$87.92
55
EV/EBIT
$57.54
$75.90
$94.26
66
EV/EBITDA
$54.46
$71.79
$89.13
67
EV/Revenue
$41.77
$58.62
$75.47
54
Asset-Based
NCAV (Graham)
$10.37
$13.90
$20.75
54
Growth DCF
Growth DCF
$20.11
$31.22
$48.43
77
Rev-Margin DCF
$33.60
$58.48
$89.18
71
Economic Profit
Residual Income
$25.13
$30.82
$45.21
75
ROIC Compounder
$31.69
$40.79
$52.50
72
Growth Earnings
Growth-Adj P/E
$51.05
$72.92
$94.80
67
Notify me when CHEOF reaches fair value
Put CHEOF on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Quality Score breakdown
Overall quality
70/100
Of which business quality 66 · Market factors (momentum, volatility) 29
Profitability
76
Margins and returns on capital today
Quality Growth
49
Are margins and returns improving?
Cashflow
31
Earnings quality: real cash, not paper profit
Fin. Strength
86
Balance sheet, leverage, solvency risk
Investment
80
Disciplined investing over empire-building
Low Volatility
50
Calm price path (market factor)
Momentum
26
Price trend over the last 3–12 months (market factor)
52W Momentum
11
Distance to the 52-week high (market factor)
Net Issuance
83
Share count: buybacks or dilution?
Revenue & earnings trend
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.
74/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+4.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+12.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+12.2%
Start year 2020 (pandemic). Over 10 years: +9.7% a year
Revenue growth 29 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+12.7%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
+8.6%
Earnings growth per share plus dividend.
Earnings per share, growth per year+4.0%
Dividend (yield on the price)4.6%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.4.0% vs 8.8%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.−19% → 17%
Start year 2020 (pandemic)
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+27.9%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+1.6%
Yearly sales growth analysts expect, extended to five years.
After inflation (figures in AUD, Australia: IMF forecast 3.0% a year to 2030, 2.9% from 2016 to 2025) that is about +24.2% a year for the price and −1.3% for the forecasts.
Forecast 2026 (sales)+1.6%
Forecast 2027 (sales)+1.6%
Projected 2028 (sales)+1.6%
Projected 2029 (sales)+1.7%
Projected 2030 (sales)+1.7%
CHEOF screens overvalued: fair value 32% below the price. Compare with Abbott Laboratories, →
Recent news
News mood ⓘNews mood, the average tone of recent news (99 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation.
Positive
Recent news coverage is more positive than average.
- Cochlear Reaches More Than 1 Million Hours of Patient Experience Across Its Fully Implantable Hearing Technology Research Program
- Cochlear Ltd's Dividend Analysis
- Cochlear Ltd (CHEOF) (FY 2026) Earnings Call Highlights: Navigating Market Headwinds with Nexa ...
- Cochlear introduces the new Osia® 3 Sound Processor
Compare Cochlear Limited with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 326 stocks
Beats the industry median on 9/14 measures
Overall it ranks above its industry peers.
Valuation Multiplesvs Medical Devices median · lower = cheaper
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- Undervalued stocks: US Stocks
- Valuation of the USA market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
None of the checked exposures detected
Similar stocks
10 more Medical Devices stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABT | $98.83 | $74.79 | −24% |
| Medtronic plc MDT | $87.09 | $65.61 | −25% |
| Stryker Corporation SYK | $278.77 | $306.65 | +10% |
| Boston Scientific Corporation BSX | $43.65 | $48.02 | +10% |
| Edwards Lifesciences Corporation EW | $85.19 | $81.94 | −4% |
| Siemens Healthineers AG SHL | €37.86 | €35.19 | −7% |
| DexCom, Inc DXCM | $86.68 | $95.35 | +10% |
| GE HealthCare Technologies Inc GEHC | $66.63 | $70.37 | +6% |
| Shenzhen Mindray Bio-Medical Electronics Co 300760 | ¥153.86 | ¥169.25 | +10% |
| Koninklijke Philips N.V PHIA | €21.87 | €15.23 | −30% |
Explore undervalued stocks
More undervalued Healthcare stocks →
All undervalued stocks
TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
🥇 Backtested Best
🏆 Big Names
⭐ Top Rated
💎 Quality on Sale
🚀 Profitable Growth
🧊 Quality Compounders
💵 Dividend Stars
📈 Strong Momentum
📉 Fallen Angels
⚖️ Deeply Undervalued
🔍 Small-Cap Gems
🏰 Moat at a Fair Price
💼 Insider Buying
🎩 Buffett-Style Quality
📚 Peter Lynch GARP
🧮 Greenblatt Magic Formula
🛡️ Graham Defensive
Discover tools
Stock screenerFilter by region, size and sector
Compare toolTwo stocks side by side
Extrinsic Value Calculator…Calculator with industry benchmark
Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
Frequently asked questions
Is Cochlear Limited (CHEOF) overvalued or undervalued?
As of Sep 23, 2026, our model estimates a fair value of $63.79 versus a price of $93.61, about −32% upside (overvalued).
What is the fair value of CHEOF?
Our model-based fair value for Cochlear Limited is $63.79 (as of Sep 23, 2026), built from audited fundamentals. The current price: $93.61.
What is the quality score of CHEOF?
Cochlear Limited has a Quality Score of 70/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Cochlear Limited (CHEOF)?
Our model-based price target is the fair value of $63.79 (as of Sep 23, 2026) from 26 valuation models. Cautious scenario $35.64, optimistic scenario $90.53. It is a calculation from audited fundamentals, not an analyst target.
What is the Cochlear Limited stock forecast for 2026?
Our models put fair value at $63.79, about −32% upside versus a price of $93.61 (overvalued). Cautious scenario $35.64, optimistic scenario $90.53. The calculation is refreshed regularly with new filings.
What is the revenue of Cochlear Limited (CHEOF)?
Cochlear Limited reported trailing-twelve-month revenue of about A$2.3B (latest available figure, as of Sep 23, 2026).
Does Cochlear Limited pay a dividend?
Cochlear Limited currently shows a dividend yield of about 4.59% relative to its recent price (as of Sep 23, 2026).
What growth is priced into Cochlear Limited (CHEOF)?
For today's price to be fair in a discounted-cash-flow model, Cochlear Limited would have to grow free cash flow by +27.9 % per year for five years (discount rate 8.5 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +12.2 % per year. As of Sep 23, 2026.
What discount rate (WACC) does the fair value of CHEOF use?
Our models discount Cochlear Limited at 8.5 %: a base by market capitalisation (mid), damped by beta 0.25, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Cochlear Limited that is +27.9 % per year a year over ten years, using the same discount rate (8.5 %) and the same formula as our fair value.
How much growth has Cochlear Limited (CHEOF) delivered so far?
Over the past 5 years revenue at Cochlear Limited grew +12.2 % a year. The price currently implies +27.9 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Cochlear Limited (CHEOF) growing?
The median revenue growth in the sector is +5.1 % a year. That is the yardstick for the growth priced into Cochlear Limited (+27.9 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Cochlear Limited (CHEOF)?
The free-cash-flow yield on the price is 1.53 %: that much free cash flow Cochlear Limited produces per unit of market value. When it exceeds the discount rate of our models (8.5 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Cochlear Limited (CHEOF)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Cochlear Limited it is $63.79 per share (as of Sep 23, 2026), against a price of $93.61. It is the blended result of 26 valuation models (cash flow, earnings, asset, dividend).
Is Cochlear Limited stock overvalued or undervalued in 2026?
As of Sep 23, 2026, CHEOF trades above its calculated fair value: price $93.61, fair value $63.79, a gap of about −32% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of CHEOF?
No. The price is what the market pays today ($93.61); the fair value is what the company's own numbers justify ($63.79). For Cochlear Limited the two are $29.82 per share apart. That gap is exactly why we show both numbers side by side.
How much is Cochlear Limited worth?
The market values Cochlear Limited at about $6.1B (market capitalisation, as of Sep 23, 2026). Per share that is $93.61; our models calculate a fair value of $63.79 per share.
What do the bullish and bearish scenarios say about CHEOF?
Our models span a range for Cochlear Limited: cautious scenario $35.64, base $63.79, optimistic $90.53 per share (as of Sep 23, 2026, price $93.61). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of CHEOF?
Cochlear Limited trades at a price-to-earnings ratio of 25.1 (as of Sep 23, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $63.79 is built from several models across several years. Other multiples: P/B 2.6, P/S 2.1, EV/EBITDA 8.5.
How solid is the balance sheet of Cochlear Limited (CHEOF)?
Balance-sheet figures for Cochlear Limited (as of Sep 23, 2026): return on equity 18.2%, debt of 0.02 per unit of equity. They feed the Quality Score of 70/100, which measures business quality independently of the share price.
How far is CHEOF from its 52-week high?
Cochlear Limited trades at $93.61, about 52% below its 52-week high of $194.55 and 45% above the low of $64.39 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of $63.79 is for.
Which stocks are comparable to Cochlear Limited?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Cochlear Limited stock attractive at the current price?
The data as of Sep 23, 2026: price $93.61, calculated fair value $63.79 (−32%), Quality Score 70/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of CHEOF calculated?
We run Cochlear Limited through 26 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $63.79, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Cochlear Limited itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Cochlear Limited (CHEOF)?
The closing price on Oct 2, 2026 was $93.61. Our model-based fair value is $63.79, about −32% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Cochlear Limited right now?
A high-quality business (quality 70/100), yet the market already pays well above fair value. Quality at a full price, with little margin of safety. The price sits above even our optimistic bull case ($90.53). The favourable scenario is already priced in. A fairly wide model range ($35.64 to $90.53) leaves room in how you read the outcome.
Where does the earnings growth of Cochlear Limited (CHEOF) come from?
Earnings per share at Cochlear Limited grew +8.7 % a year from 2014 to 2025. Broken into its drivers: revenue per share +7.9 %, EBIT margin −0.2 %, tax rate −0.1 %, residual (interest, one-offs) +1.1 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Cochlear Limited
How large is the market capitalisation of Cochlear Limited (CHEOF)?
The market capitalisation of Cochlear Limited is $6.1B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Cochlear Limited (CHEOF)?
The price-to-sales ratio of Cochlear Limited is 4.17 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Cochlear Limited (CHEOF)?
Earnings per share at Cochlear Limited are $3.73 (price ÷ EPS = P/E 25.1). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Cochlear Limited (CHEOF)?
The dividend yield of Cochlear Limited is 4.6% (payout 115%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Cochlear Limited (CHEOF)?
The net margin of Cochlear Limited is 16.6% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Cochlear Limited (CHEOF)?
The return on equity (ROE) of Cochlear Limited is 18.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Cochlear Limited (CHEOF)?
On an EBIT basis the return on assets of Cochlear Limited is 15.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Cochlear Limited (CHEOF)?
The operating margin of Cochlear Limited is 21.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Cochlear Limited (CHEOF)?
Revenue at Cochlear Limited is growing −0.4% versus a year earlier (3y avg +12.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Cochlear Limited (CHEOF)?
Earnings per share at Cochlear Limited are growing −21.1% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does Cochlear Limited (CHEOF) hold?
Cochlear Limited holds more cash than debt, A$40.0M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Cochlear Limited in the live analysis
One click puts Cochlear Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.